Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    Stewart AK, Fonseca R . Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23: 6339–6344.

  2. 2

    Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269–277.

  3. 3

    Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284.

  4. 4

    Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467–472.

  5. 5

    Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27: 4585–4590.

  6. 6

    Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007; 13: 1066–1072.

  7. 7

    Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008; 14: 6033–6041.

  8. 8

    Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A et al. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010; 24: 833–842.

  9. 9

    Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011; 17: 7776–7784.

  10. 10

    Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014; 28: 675–679.

  11. 11

    Chang H, Ning Y, Qi X, Yeung J, Xu W . Chromosome 1p21 deletion is a novel prognostic marker in patients with multiplemyeloma. Br J Haematol 2007; 139: 51–54.

  12. 12

    Li F, Xu Y, An G, Hu LP, Zhang YR, Li ZJ et al. The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment. Zhonghua Xue Ye Xue Za Zhi 2013; 34: 862–867.

  13. 13

    Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010; 116: e56–e65.

  14. 14

    Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F et al. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget 2015; 6: 9434–9444.

  15. 15

    Chang H, Qi X, Jiang A, Xu W, Young T, Reece D . 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010; 45: 117–121.

Download references


This study was supported by grants from the National Natural Science Foundation of China (81172255, 81360353, 81400150), Science and Technology Infrastructure Program of Tianjin (12ZCDZSY17600), the Ministry of Science and Technology of China (2010DFB30270), Science Fund for Creative Research Groups (81421002), the Science and Technology Support Program of Jiangxi province (20141BBG70028), Science and Technology Cooperation Program (20151BDH80043) and Young Scientist Training Program (20153BCB23040) of Jiangxi Province. Supplementary Information accompanies this paper on the Leukemia website (

Author information

Correspondence to L Qiu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Supplementary Information (DOC 480 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading